RT Journal Article
SR Electronic
T1 An FDA-approved assay platform can detect biomarkers of neuronal and glial injury in the blood of COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.02.24306477
DO 10.1101/2024.05.02.24306477
A1 Glushakov, Alexander V.
A1 Vittor, Amy Y.
A1 Lewis, Lawrence
A1 House, Stacey
A1 Bartlett, Maggie L.
A1 Glushakova, Olena Y.
A1 Urbine, Dan
A1 Smith, Darci R.
A1 Hayes, Ronald L.
YR 2024
UL http://medrxiv.org/content/early/2024/05/03/2024.05.02.24306477.abstract
AB Employing assays approved by the U.S. Food and Drug Administration (FDA) to assist in detection of brain injury in mild traumatic brain injury (TBI) patients, this study demonstrated that the astroglial protein, glial fibrillary acidic protein (GFAP) and the neuronal protein, ubiquitin C-terminal hydrolase (UCH-L1) were positively associated with age in COVID-19 patients. Controlling for age, UCH-L1 and GFAP were significantly elevated in COVID-19 patients compared to non-COVID-19 controls, and UCH-L1, but not GFAP, was elevated in patients with neurological alterations. Data from this study are also compared to historical data on levels of UCH-L1 and GFAP in brain injured and healthy normal patients. These data support further studies of an FDA approved assay format that could facilitate timely development, validation, and FDA approval of blood tests to detect neuronal and glial cell injuries following infection by SARS-CoV-2. Moreover, appropriately validated blood tests could detect brain injury originating from any systemic pathogen.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research leading to the results of this study was not supported by extramural funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Barnes-Jewish Hospital ED-in St. Louis (IRB#202007018) IRB of University of Florida (IRB#202003085, IRB#202001993)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe assay results, patient clinical characteristics and selected unidentified demographic data are provided as supplemental materials.